This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.
Inclusion Criteria: - To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.
Exclusion Criteria: - Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
UCLA Medical Center
Torrance, California, 90505
Investigator: Dr. Parvin Fatheddin Peddi
Fort Wayne Oncology & Hematology
Fort Wayne, Indiana, 46804
Investigator: Dr. Sunil Babu
Sarah Cannon Cancer Center
Nashville, Tennessee, 37203
Investigator: Dr. Howard A. Burris III
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST)
Eli Lilly and Company